HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ: GANX ) with a Buy and maintains $8 price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.